Related Experiment Videos

Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B

Fatih Erbey1, Emine Kocabaş, İbrahim Bayram

  • 1Division of Pediatric Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey. erbeyfa@gmail.com

Tuberkuloz Ve Toraks
|January 8, 2013
PubMed

Insights

Pulmonary mucormycosis treatment with liposomal amphotericin B is standard care, though optimal dosing remains unclear. This case details a high cumulative dose administered to a pediatric patient, contributing to treatment knowledge.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pediatric Medicine

Background:

  • Pulmonary mucormycosis is a severe fungal infection, often treated with Amphotericin B.
  • Establishing optimal dosing for liposomal amphotericin B in pediatric cases is crucial for effective treatment.
  • Limited data exists on high-dose liposomal amphotericin B administration in pediatric pulmonary mucormycosis.

Observation:

  • A case of pulmonary mucormycosis in a pediatric patient is presented.
  • The patient received a cumulative dose of 42.55 grams of liposomal amphotericin B over 45 weeks.
  • This represents one of the highest documented doses of liposomal amphotericin B in a pediatric patient for this condition.

Findings:

  • The case highlights the feasibility of administering high cumulative doses of liposomal amphotericin B.
  • This administration was part of the medical treatment for pulmonary mucormycosis.
  • The study contributes to understanding the upper limits of liposomal amphotericin B dosing in pediatric patients.

Implications:

  • Findings may inform future treatment guidelines for pediatric pulmonary mucormycosis.
  • Further research is needed to establish definitive optimal dosing and safety profiles.
  • This case provides valuable real-world data for clinicians managing severe fungal infections in children.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...